J2779Drugs Administered Other than Oral Method

Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg

Short description: Inj, susvimo 0.1 mg

Effective date: July 1, 2022
Termination date: —

Related codes (J-series)

J0013Esketamine, nasal spray J0014Cocaine hcl nasal (goprelto)J0120Tetracyclin injection J0121Inj., omadacycline, 1 mg J0122Inj., eravacycline, 1 mg J0129Abatacept injection J0130Abciximab injection J0131Inj, acetaminophen (nos)J0132Acetylcysteine injection J0133Acyclovir injection J0134Inj acetaminophen -fresenius J0135Adalimumab injection

Frequently asked questions

What is HCPCS code J2779?

J2779 is a HCPCS Level II code for Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg.

What category is HCPCS code J2779 in?

J2779 falls under the Drugs Administered Other than Oral Method category of HCPCS Level II.

When did HCPCS code J2779 become effective?

J2779 has been effective since July 1, 2022, per CMS's quarterly HCPCS update.

HCPCS Level II data from CMS (public domain). HCPCS Level I (CPT) codes are not included — CPT is copyrighted by the American Medical Association. Always verify codes with authoritative sources before making coding or billing decisions.